News Releases

May 08, 2019
Sangamo Therapeutics Reports First Quarter 2019 Financial Results
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time BRISBANE, Calif. , May 8, 2019 /PRNewswire/ --  Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported first quarter 2019 financial results and recent business highlights.
Additional Formats
PDF Version
Apr 08, 2019
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
RICHMOND, Calif. , April 8, 2019 /PRNewswire/ --  Sangamo Therapeutics, Inc.  (Nasdaq: SGMO) today announced the completion of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a price to the public of $11.50 per share, including 1,650,000 shares sold
Additional Formats
PDF Version
Apr 03, 2019
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
RICHMOND, Calif. , April 3, 2019 /PRNewswire/ --  Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Sangamo. In addition, Sangamo expects to grant the underwriters of
Additional Formats
PDF Version
Displaying 1 - 10 of 26